150 related articles for article (PubMed ID: 28765916)
1. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
3. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
4. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Lee M; Kang SY; Suh YL
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.
Yoon SJ; Son HY; Shim JK; Moon JH; Kim EH; Chang JH; Teo WY; Kim SH; Park SW; Huh YM; Kang SG
J Transl Med; 2020 Dec; 18(1):482. PubMed ID: 33317554
[TBL] [Abstract][Full Text] [Related]
6. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
[TBL] [Abstract][Full Text] [Related]
7. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
8. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India.
Trivedi T; Panchal K; Bhalala N; Trivedi P
J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028
[TBL] [Abstract][Full Text] [Related]
10. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
[TBL] [Abstract][Full Text] [Related]
11. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
13. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
[TBL] [Abstract][Full Text] [Related]
14. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
16. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
Quan AL; Barnett GH; Lee SY; Vogelbaum MA; Toms SA; Staugaitis SM; Prayson RA; Peereboom DM; Stevens GH; Cohen BH; Suh JH
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):695-703. PubMed ID: 15936158
[TBL] [Abstract][Full Text] [Related]
18. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
19.
Senhaji N; Louati S; Chbani L; El Fatemi H; Hammas N; Mikou K; Maaroufi M; Benzagmout M; Boujraf S; El Bardai S; Giry M; Marie Y; Chaoui El Faiz M; Mokhtari K; Idbaih A; Amarti A; Bennis S
Biomed Res Int; 2017; 2017():8045859. PubMed ID: 28785587
[TBL] [Abstract][Full Text] [Related]
20. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
Montgomery RM; Queiroz Lde S; Rogerio F
Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
